OncoMed Pharmaceuticals Inc Operating Cash Flow
OncoMed Pharmaceuticals Inc reported Operating Cash Flow of -$44.86 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-07.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2019-03-07
- OncoMed Pharmaceuticals Inc net cash provided by (used in) operating activities for the quarter ending 2018-12-31 was -$13.41M.
- OncoMed Pharmaceuticals Inc net cash provided by (used in) operating activities for the quarter ending 2018-09-30 was -$8.81M.
- OncoMed Pharmaceuticals Inc net cash provided by (used in) operating activities for the quarter ending 2017-12-31 was -$12.35M.
- OncoMed Pharmaceuticals Inc net cash provided by (used in) operating activities for the quarter ending 2017-09-30 was -$16.53M.
- OncoMed Pharmaceuticals Inc net cash provided by (used in) operating activities for fiscal 2018 was -$44.86M.
- OncoMed Pharmaceuticals Inc net cash provided by (used in) operating activities for fiscal 2017 was -$84.97M.
- OncoMed Pharmaceuticals Inc net cash provided by (used in) operating activities for fiscal 2016 was -$36.94M.
- OncoMed Pharmaceuticals Inc net cash provided by (used in) operating activities for fiscal 2013 was $144.54M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$13.41M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$22.22M derived: sum of 2 quarters · filed 2019-03-07 | -$44.86M 10-K · filed 2019-03-07 | |
| 2018-09-30 | -$8.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$31.45M 10-Q · filed 2018-11-01 | ||
| 2018-06-30 | -$22.64M 10-Q · filed 2018-08-02 | |||
| 2017-12-31 | -$12.35M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$28.88M derived: sum of 2 quarters · filed 2019-03-07 | -$84.97M 10-K · filed 2019-03-07 | |
| 2017-09-30 | -$16.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$72.62M 10-Q · filed 2018-11-01 | ||
| 2017-06-30 | -$56.09M 10-Q · filed 2018-08-02 | |||
| 2016-12-31 | -$36.94M 10-K · filed 2019-03-07 | |||
| 2013-12-31 | $167.30M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-18 | $154.24M derived: sum of 2 quarters · filed 2014-03-18 | $144.54M 10-K · filed 2014-03-18 | |
| 2013-09-30 | -$13.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | -$22.75M 10-Q · filed 2013-11-13 | ||
| 2013-06-30 | -$9.69M 10-Q · filed 2013-09-03 | |||
| 2012-12-31 | -$8.76M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-18 | -$9.39M derived: sum of 2 quarters · filed 2014-03-18 | -$33.34M 10-K · filed 2014-03-18 | |
| 2012-09-30 | -$628.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | -$24.59M 10-Q · filed 2013-11-13 | ||
| 2012-06-30 | -$23.96M 10-Q · filed 2013-09-03 | |||
| 2011-12-31 | -$11.29M 10-K · filed 2014-03-18 |